SEC Form 13F
| Report period | 2026-06-30 |
|---|---|
| Publicly available | 2026-08-15 |
| Reported value | $541,855,576 |
| Positions | 48 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| ABIVAX SA | ABVX | SPONSORED ADS | $68,821,727 | 516,447 |
| INSMED INC | INSM | COM PAR $.01 | $62,804,724 | 589,052 |
| TREVI THERAPEUTICS INC | TRVI | COM | $41,232,390 | 2,210,852 |
| BRIGHTSPRING HEALTH SVCS INC | BTSG | COM | $36,077,548 | 517,315 |
| REVOLUTION MEDICINES INC | RVMD | COM | $34,719,839 | 185,390 |
| ARGENX SE | ARGX | SPONSORED ADR | $27,590,952 | 29,739 |
| ALKERMES PLC | ALKS | SHS | $23,523,469 | 448,964 |
| TRAVERE THERAPEUTICS INC | TVTX | COM | $19,260,465 | 339,033 |
| ASTRAZENECA PLC | AZN | ORD | $18,654,057 | 98,376 |
| NEWAMSTERDAM PHARMA COMPANY | NAMS | ORDINARY SHARES | $17,078,391 | 503,936 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.